Colin D Weekes
Massachusetts General Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Colin D Weekes as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 17:01 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05417386 · FOLFIRINOX + NIS793 in Pancreatic CancerColin D. Weekes, M.D., PhD · terminated · Pancreas Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma · principal investigator
- Ph2NCT05077800 · FOLFIRINOX + Elraglusib + Losartan In Pancreatic CancerColin D. Weekes, M.D., PhD · active not recruiting · Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 17:01 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 17:01 UTC. The ranking covers the 200 most relevant of 29 PubMed records, and a shared surname and initials can bring in a namesake. All 29 on PubMed
- 458 citationsRCR 17.4
- Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial.Nat Cancer · 2021251 citationsRCR 11.9
- Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial.Nat Med · 2024243 citationsRCR 26.9
- First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.J Clin Oncol · 2018125 citationsRCR 3.8
- A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.Br J Cancer · 2017107 citationsRCR 3.2
- Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer.Mol Cancer Ther · 201699 citationsRCR 3.1
- A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors.Invest New Drugs · 201479 citationsRCR 2.0
- 74 citationsRCR 13.3
- Hodgkin's disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen.J Clin Oncol · 200269 citationsRCR 1.5
- A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors.Cancer Chemother Pharmacol · 201468 citationsRCR 1.8